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Toll-like receptors (TLRs) are pattern recognition receptors that recognize conserved struc-
tures in pathogens, trigger innate immune responses, and prime antigen-speciﬁc adaptive
immunity. Elucidation of crystal structures of TLRs interacting with their ligands such as
TLR1-2 with triacylated lipopeptide, TLR2-6 with diacylated lipopeptide, TLR4–MD-2 with
LPS, and TLR3 with double-stranded RNA (dsRNA) have enabled an understanding of the
initiation of TLR signaling. Agonistic ligands such as LPS, dsRNA, and lipopeptides induce
“m” shaped TLR dimers in which C-termini converge at the center. Such central conver-
gence is necessary to bring the two intracellular receptorTIR domains closer together and
promote their dimerization, which serves as an essential step in downstream signaling.
In this review, we summarize TLR ECD structures that have been reported to date with
special emphasis on ligand recognition and activation mechanism.
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INTRODUCTION
The Toll-like receptor (TLR) protein family plays an important
role in the innate immune system by recognizing common struc-
tural patterns in diverse microbial molecules (Gay and Gangloff,
2007). TLRs are type I transmembrane glycoproteins character-
ized by the presence of an extracellular domain (ectodomain;
ECD) containing leucine rich repeats (LRRs), which is primarily
responsible for mediating ligand recognition, followed by a single
transmembrane helix and an intracellular Toll-like/interleukin-1
(IL-1) receptor (TIR) domain that is responsible for downstream
signaling. To date, 10 and 12 functional TLRs have been iden-
tiﬁed in humans and mice, respectively. TLR1-9 is conserved in
both species; however, mouse TLR10 is not functional because
of a retrovirus insertion, and TLR11-13 have been lost from the
human genome (Kawai and Akira, 2010). “Toll” was ﬁrst identi-
ﬁed as a protein important in the early stages of development in
Drosophila. Later, it was discovered that Toll signals to Dorsal (like
mammalian NF-κB) and is involved in the coordination of anti-
fungal and antibacterial responses (Rosetto et al., 1995; Lemaitre
et al., 1996).
The TLR family can be largely divided into two subgroups,
extracellular and intracellular, depending on their cellular local-
ization. TLR1, 2, 4, 5, 6, and 10 are largely localized on the cell
surface to recognize PAMPs. Conversely, TLR3, 7, 8, and 9 are
localized in intracellular organelles such as endosomal/lysosomal
compartments and the endoplasmic reticulum (ER). Among the
TLRs, the ligand (lipopolysaccharide; LPS) of TLR4 was ﬁrst iden-
tiﬁed by genetic studies (Lemaitre et al., 1996). Lipopeptides or
lipoproteins are recognized by TLR2 in complex with TLR1 or 6,
while viral double-stranded RNA (dsRNA) is recognized by TLR3,
ﬂagellin is recognized by TLR5, single-stranded RNA is recognized
by TLR7 and 8, and host- or pathogen-derived DNA is recog-
nized by TLR9. In addition to known pathogen/microbial derived
ligands, TLR also recognizes the endogenous ligands (produced
by stressed or damaged cells) and synthetic ligands listed in
Table 1.
The commonmechanismof TLR signaling is that interaction of
an agonist with the ECD either induces the formation of a recep-
tor dimer, or changes the conformation of a pre-existing dimer
(Latz et al., 2007; Zhu et al., 2009) in such a way that it brings two
intracellular TIR domains of the TLRs to interact physically. This
simple rearrangement serves as a nucleating act for the recruitment
of downstream signaling adapter proteins (Jin and Lee, 2008). Sig-
naling cascades via the intracellular TIR domains are mediated by
speciﬁc adaptormolecules such asMyd88 (Myeloid differentiation
factor 88), Mal (Myd88 adaptor like), TRIF (TIR domain con-
taining adaptor inducing interferon-β), and TRAM (TRIF related
adaptor molecule). These adaptor proteins also contain TIR
domains that mediate TIR–TIR interactions between TLR recep-
tors, receptor–adaptor, and adaptor–adaptor interactions that are
critical for signaling (Palsson-Mcdermott and O’Neill, 2007). In
general, intracellular TIR domain of adaptor proteins are com-
posed of approximately 160 amino acid residues and the primary
sequences of TIR domains are characterized by three conserved
sequence boxes designated Box 1, 2, and 3. Box 1 is considered
to be the signature sequence of the family, whereas boxes 2 and
3 contain functionally important residues involved in signaling
(Carpenter and O’Neill, 2009). These processes result in the for-
mation of a large multimer complex, or “signaling platform,” that
propagates downstream signaling, eventually leading to changes
in the expression of several hundred primary immune response
genes. However, the architecture of the TLR signaling complexes
is poorly understood at this time due to a lack of reliable meth-
ods to study such interactions as well as the inherent weaknesses
of individual inter- and intra-protein interactions in transitory
complexes.
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Table 1 | Toll-like receptors and their principal ligands.
TLRs Localization Ligands
Exogenous Endogenous Synthetic
analogs
Fully synthetic
molecules
TLR1 Plasma
membrane
Lipopeptides (Bacteria and Mycobacteria)
Soluble factors (Neisseria meningitidis)
Triacyl lipopeptides
TLR2 Plasma
membrane
Lipoprotein/lipopeptides (Gram-positive
bacteria, Mycoplasma, Mycobacteria,
Spirochetes)
Peptidoglycan (Gram-positive bacteria)
Lipoteichoic acid (Gram-positive bacteria)
Phenol-soluble modulin (Staphylococcus
epidermidis)
Heat-killed bacteria (Listeria monocytogenes)
Porins (Neisseria)
Atypical lipopolysaccharides (Leptospira
interrogans, Porphyromonas gingivalis)
Soluble factors (Neisseria meningitidis)
Glycolipids (Treponema maltophilia)
Outer membrane protein A (Klebsiella
pneumonia)
Glycoinositolphospholipids (Trypanosoma
cruzi )
Phospholipomannan (Candida albicans)
Structural viral proteins (Herpes simplex
virus, Cytomegalovirus)
Hemagglutinin (Measles virus)
Lipoarabinomannan (Mycobacteria)
Zymosan (Saccharomyces)
HSP60 HSP70
HSP96 HMGB1
Hyaluronic acid
Diacyl and triacyl
lipopeptides
TLR3 Endolysosome Single-stranded viral RNA (ssRNA) and
double-stranded RNA (dsRNA; Viruses)
mRNA Poly(I:C)
Poly(I:C12U)
TLR4 Plasma
membrane
Lipopolysaccharide (Gram-negative bacteria)
HSP60 (Chlamydia pneumonia)
Envelope proteins (Respiratory syncytial virus
and mouse mammary tumor virus)
Fusion protein (syncytial virus)
Glycoinositolphospholipids (Trypanosoma
cruzi )
Taxol (Plant product)
HSP22
HSP60
HSP70 HSP96
HMGB1
β-defensin 2
Extra domain A of
ﬁbronectin
Hyaluronic acid
Heparan sulfate
Fibrinogen
Surfactant-protein A
Lipid A mimetics
(Monophosphoryl
lipid A, aminoalkyl
glucosamine
4-phosphate)
E6020
E5531
E5564
TLR5 Plasma
membrane
Flagellin (Gram-positive or Gram-negative
bacteria)
Discontinuous 13-
amino acid peptide
CBLB502
TLR6 Plasma
membrane
Diacyl lipopeptides (Mycoplasma)
Lipoteichoic acid (Gram-positive bacteria)
Phenol-soluble modulin (Staphylococcus
epidermidis)
Zymosan (Saccharomyces)
Heat-liable soluble factor (Group B
streptococcus)
Diacyl lipopeptides
(Continued)
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Table 1 | Continued
TLRs Localization Ligands
Exogenous Endogenous Synthetic
analogs
Fully synthetic
molecules
TLR7 Endolysosome Single-stranded RNA (Viruses) Endogenous RNA Oligonucleotides Imidazoquinolines
(Imiquimod,
Resiquimod)
Guanosine
nucleotides
(Loxoribine, Isatoribine)
Bropirimine
TLR8 Endolysosome Single-stranded RNA (Viruses) Endogenous RNA Imidazoquinolines
(Resiquimod)
TLR9 Endolysosome Unmethylated CpG motifs (Bacteria and
viruses)
Hemozoin (Plasmodium)
Endogenous DNA CpG oligodeoxynu-
cleotides (CPG 7909,
CPG 10101, 1018 ISS)
TLR10 Extracellular Unknown, may interact with TLR2 andTLR1
TLR11 Plasma
membrane
Proﬁling-like molecule (Toxoplasma gondii )
Structural studies of TLR–ligand complexes have been an
attractive area of research that has enabled a better under-
standing of the structure based activation of innate immunity.
Such information is essential for the development of adjuvants
that speciﬁcally bind to TLR ECD and activate its signaling
and also in the development of anti-inﬂammatory drugs that
block TLR mediated signaling. To date, ﬁve TLR–ligand struc-
tures (TLR1–TLR2–Pam3CSK4, TLR2–TLR6–Pam2CSK4, TLR4–
MD-2–Eritoran,TLR4–MD-2–LPS, andTLR3–dsRNA) have been
determined (Jin et al., 2007; Kim et al., 2007b; Liu et al., 2008; Kang
et al., 2009; Park et al., 2009). Currently, these solved atomic mod-
els can be used as templates to predict the structures of other
unknown TLRs. In this review article, we discuss how similar
structures of TLR ECD LRRs have evolved to bind a wide array of
different ligands and their activation mechanism.
GENERAL STRUCTURE OF TLR ECDs
The ECD of TLR members contains multiple blocks of LRR,
which are protected by cysteine rich regions to form cap-like
structures at the LRR-N- and -C-terminal ends. The C-terminal
capping structure of TLRs is connected to the cytoplasmic TIR
domain via a single transmembrane α helix. Individual LRR
module (approximately 20–30 amino acid residues long) con-
sists of conserved “LxxLxLxxNxL” motifs and a variable region
(Figure 1A). The conserved leucine residue in these motifs can be
substituted by other hydrophobic amino acids (Matsushima et al.,
2007). The asparagine residues that are also present in the motif
form continuous H-bonds with the backbone carbonyl group of
neighboring strands throughout the entire protein, resulting in
an asparagine ladder. These conserved asparagine residues are
important in maintaining the overall shape of the ECD, which
can also be replaced by other residues such as cysteine, threonine,
or serine, which are able to form H-bonds (Kajava et al., 1995;
Kobe and Deisenhofer, 1995; Bell et al., 2003). The variable “x”
residues present in the motif are exposed to the solvent. Among
them, only few residues are involved in ligand recognition. The
“LxxLxLxxNxL” motifs located in the inner concave surfaces of
the horseshoe-like structure form parallel β-strands, whereas the
variable region forms a convex surface generated by α helices, β-
turns, and loop structures (Figure 1A). LRR proteins are present
in a very large and diverse group of proteins and have been found
to be involved in a wide variety of physiological functions includ-
ing immune responses, signal transduction, cell cycle regulation,
enzyme regulation, and transcriptional regulation (Buchanan and
Gay, 1996; Dolan et al., 2007).
The crystallization of some LRR proteins, including TLRs, has
proven to be very difﬁcult. This problem was overcome by the
introduction of a new method known as the “hybrid LRR tech-
nique” (Jin et al., 2007; Kim et al., 2007a,b; Kang et al., 2009; Park
et al., 2009). Hagﬁsh variable lymphocyte receptors (VLRs) were
chosen as fusion partners, and the TLR and VLR were fused at
their conserved LxxLxLxxNxL motifs. Interestingly, the TLR–VLR
hybrid demonstrated that the structure and function of the fusion
proteins were not altered. Some hybrids fail to form soluble pro-
teins due to the atomic collisions or the exposed hydrophobic core
at the fusion sites. However, hybrids that produced soluble pro-
teins formed stable heterodimers and possibly bound with ligands
that were used for the crystallographic studies (Jin et al., 2007; Kim
et al., 2007a,b; Kang et al., 2009; Park et al., 2009).
The LRR protein family can be classiﬁed into seven sub-
families based on their sequence and structural patterns. TLR
belongs to the typical subfamily of the LRR superfamily (Kobe
and Kajava, 2001; Matsushima et al., 2007). Each LRR region con-
sists of 24 amino acid residues, possesses the conserved motif,
xLxxLxxLxLxxNxLxxLPxxxFx, and displays a unique horseshoe
shape structure (Figure 1B). LRR modules of TLR1, 2, 4, and 6,
but notTLR3,have been shown todeviate from their conformation
and lengthwhen comparedwith other typicalmembers (Kimet al.,
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FIGURE 1 | Structure of Leucine rich repeats. (A) LRR consensus repeats
for TLR4. Residues forming the hydrophobic core, asparagine ladder and
variable regions are mentioned. Secondary structure of LRR, the residues
forming the hydrophobic core is highlighted in a box and the remaining portion
of the LRR forming the convex surface. (B) Ribbon diagram of TLR3–ECD:
LRR domain has uniform β sheet angles and a continuous asparagine
network. (C) Ribbon diagram of TLR4 ECD showing the position of three sub
domains: N-terminal, Central, and C-terminal.
2007b; Jin and Lee, 2008; Kang et al., 2009; Park et al., 2009). These
four TLRs have major structural changes in their central β-sheets;
hence, their LRR domains can be divided into an N-terminal, cen-
tral, and C-terminal domain, respectively (Figure 1C). The central
domain of TLR1, 2, 4, 6, and 10 lacks an asparagine ladder, which
is primarily responsible for the stabilization of the horseshoe-
like structure. Furthermore, this broken asparagine ladder leads
to unusual structural distortions. LRR modules of the central
domain differ considerably in the number of residues, varying
from 20 to 33. However, the LRR modules present in the majority
of LRR proteins are of uniform length (Kajava et al., 1995; Kobe
and Deisenhofer, 1995; Matsushima et al., 2007). LRR subfam-
ilies with shorter LRR modules encompass loops in the convex
surface, and those containing longer LRR modules have bulkier
α helices. It should be noted that helices require more space than
loops; therefore, subfamilies with α helices have smaller radii than
those with loops that generate enough space in the convex region
(Jin and Lee, 2008; Kang and Lee, 2011). This anomaly explains
the structural conformation variations of TLR receptors and the
ability of the receptor to bind with diverse ligands as well as
co-receptors.
CRYSTALLOGRAPHIC STRUCTURES OF TLR ECD WITH THEIR
LIGANDS
To date, ﬁve crystallographic structures of the TLR ECDs and
their ligand complexes have been reported. Of those, four were
complexed with agonistic ligands and the remaining one was
complexed with a co-receptor and an antagonistic ligand. These
structures provide evidence about how pattern recognition recep-
tors (PRRs) recognize patterns present in the ligands. Additionally,
these studies suggest that ECD activation mechanisms are also
common among all TLR receptor family members.
TLR2 COMPLEXES
Toll-like receptor-2 heterodimerizes with TLR1 or 6 to recognize
multiple PAMPs of fungi, Gram-positive pathogens and mycobac-
teria (Kawai and Akira, 2010). TLR2 recognizes lipopeptides that
are anchored to the bacterial membrane by lipid chains cova-
lently attached to N-terminal cysteine (Hantke and Braun, 1973).
Lipopeptides fromGram-negative bacteria have three lipid chains.
Two of these are attached to the glycerol through an ester bond,
which is in turn connected to the sulfur atom of the N-terminal
cysteine. The third lipid chain is connected to the amino termi-
nal via amide bonds. Lipopeptides from Gram-positive bacteria
or mycoplasma have only two lipid chains and lack the amide-
linked lipid chain (Muhlradt et al., 1997; Shibata et al., 2000).
Synthetic lipopeptide analogs (Pam2CSK4,Pam3CSK4) containing
a di- or tri-acylated cysteine group mimic the pro-inﬂammatory
properties of the lipoproteins, which conﬁrms that acylated N-
terminal cysteine is the primary motif responsible for stimu-
lating the immune response. Furthermore, TLR2 receptor also
recognizes other ligands such as lipoteichoic acid, lipomannan,
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peptidoglycan, zymosan, and phenol-soluble modulin (Zahringer
et al., 2008).
TLR1–TLR2–TRIACYLATED LIPOPEPTIDE COMPLEX
The crystal structure of TLR2 in association with TLR1 and a syn-
thetic triacylated lipopeptide, Pam3CSK4, has been determined
(Jin et al., 2007). Indeed, this is the ﬁrst crystal structure of a
TLR dimer resulting from the binding of agonists, which further
explains the ligand-induced dimerization. In this structure, the
ECD of TLR2 and 1 form an “m” shaped heterodimer, with the
two N-terminals extending in the opposite direction and the C-
terminals converging in themiddle region (Figure 2A). Pam3CSK4
consists of three lipid chains, twoof those insert into thehydropho-
bic pocket of TLR2 and the remaining one inserts into a narrow
hydrophobic channel of TLR1 (Figure 2B). Apart from the acyl
chain binding, the head groups of Pam3CSK4 also interact with
TLRs 1 and 2. In particular, TLRs form H-bonds with glycerol
and peptide backbone and also form hydrophobic interactions
with sulfur atoms. The ligand-binding pockets of TLR1 and 2 are
located at the junction of the central and C-terminal domains,
indicating the importance of structural transition in the forma-
tion of ligand-binding pockets. The ligand binding in the convex
surface of TLR2/1 was found to be quite unusual because most
ligand-binding sites onLRRproteins that havebeen identiﬁedwere
found to be present on the concave surfaces (Kobe and Deisen-
hofer, 1995). The ligandbound complex of TLR1 and2 is stabilized
by non-covalent forces such as H-bonding, hydrophobic interac-
tions and ionic interactions at the interface near the ligand-binding
pocket. It is worth noting that TLR1 P315L polymorphic varia-
tion has been reported to interfere with TLR1 signaling (Omueti
et al., 2007). In fact, this P315 residue is located at the TLR1/2
dimer interface, highlighting the importance of P315 in TLR1
and 2 heterodimerization. Moreover, species-speciﬁc lipoproteins
response has also been observed (Grabiec et al., 2004). Lipopep-
tides with shorter lipid chains act as more potent activator in
mouse than human TLR2. This phenomenon is mainly due to
the structural variations observed in the TLR2 pocket (Jin et al.,
2007).
TLR2–TLR6–DIACYLATED LIPOPEPTIDE COMPLEX
The crystal structure of TLR2 in association with TLR6 and a
synthetic diacylated lipopeptide Pam2CSK4 has been determined
(Kang et al., 2009). In this structure, the ECD of TLR2 and 6 form
an “m” shaped heterodimer, with the two N-terminals extending
in the opposite direction and the two C-terminal ends converg-
ing in the middle region (Figure 2C). The dimeric arrangement
of TLR2/6 is similar to TLR2/1 complex. However, TLR1 and 6
contain important structural differences in their ligand-binding
sites and dimerization interface. In TLR6, the side chains of two
phenylalanine (F343 and F365) residues block the lipid-binding
pocket, leading to a pocket that is less than half the length of
the TLR1 (Figure 2D). This structural feature provides selec-
tivity for diacylated over triacylated lipopeptides, as conﬁrmed
by the mutation studies of these phenylalanine residues to the
corresponding amino acids of TLR1 that rendered TLR6 fully
responsive not only to diacyl but also to triacylated lipopeptides. In
FIGURE 2 | Structures ofTLR2–TLR1/6 heterodimers induced by
lipopeptides. (A) Crystal structure of TLR1/2–Pam3CSK4 complex.
TLR1, TLR2, and Pam3CSK4 are colored in sandy brown, hot pink, and
black, respectively. (B) Lipid-binding pocket in TLR1/2–Pam3CSK4
complex. The structures of TLRs are omitted to reveal the shape of
lipid-binding pocket. (C) Crystal structure of TLR2/6–Pam2CSK4
complex. TLR2, TLR6, and Pam2CSK4 are colored in hot pink, gray,
and deep magenta, respectively. (D) Lipid-binding pocket in
TLR1/2–Pam2CSK4 complex. The lipid-binding channel is blocked by F343
and F365.
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the TLR2/6 complex, two-ester bound lipid chains of Pam2CSK4
are inserted into a hydrophobic pocket in TLR2 that is located
between the LRR11 and 12 loops. Whereas, F319 located in the
LRR11 loop of TLR6, forms an H-bond with the peptide bond of
the ligand. Such an H-bond network is absent in the TLR2–TLR1–
Pam3CSK4 structure. Moreover, TLR2-6 heterodimerization is
primarilymediated by surface exposed residues of LRR11-14mod-
ules. In the TLR2-1 complex, the amide bound lipid chain plays
an important role in bridging the two TLRs. Although Pam2CSK4
lacks these amide bound chains, it still forms a dimer, primar-
ily through hydrophobic and hydrophilic interactions of their
surface exposed residues between the two TLRs. This area of
hydrophobic interaction is 80% larger than in theTLR1/2 complex,
suggesting that this surface interaction together with the H-bond
between LRR11 and the ligand drives the heterodimerization of
TLR6.
TLR2–LPTA
During the course of TLR2–TLR6–diacylated lipopeptide com-
plex determination, TLR2 in complex with two non-peptide
ligands, Streptococcus pneumonia lipoteichoic acid (pnLTA) and
PE-DTPA (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
N -diethylenetriaminepentaacetic acid), has been determined
(Kang et al., 2009). PE-DTPA is a synthetic derivative of phos-
pholipid in which metal coordinating DTPA is attached to the
ethanolamine head group. In the monomeric TLR2–pnLTA struc-
ture, the overall horseshoe-shaped structure of TLR2 and the
ligand-binding pocket remain unchanged. When compared with
TLR2-6–Pam2CSK4, thepositionof the sugar head groupof LTAof
the TLR2–pnLTA complex displaces upward by∼5.2 Å and rotated
by 110Å toward the lateral surface of the ECD. Moreover, the
hydrogen donor and acceptor atoms in the sugar head group of
pnLTA have a different arrangement than the lipopeptides. Hence,
it is not possible to form an H-bonding network. Due to the shift,
TLR1orTLR6 cannot approachTLR2 to formheterodimers. In the
TLR2–PE-DTPA structure, the acyl chain and head group arrange-
ments are similar to those of TLR2–pnLTA. When compared with
TLR2-6 lipopeptide complexes, the head group of PE-DTPA is
shifted ∼4.3 Å. This structural shift primarily occurs due to a
lack of proper H-bonding between the ligand head group and
the TLRs, as well as to repulsion of the hydrophilic oxygen atom
of the ligand, whose corresponding position in lipopeptide con-
tains sulfur that forms a hydrophobic interactionwithTLRs. These
complexes (pnLTA and PE-DTPA) have little or no ability to acti-
vate TLR2 because of the structural shift in ligand head groups,
which strongly suggests that the ligand/lipopeptide head group
plays an important role in TLR2 activation via heterodimerization.
A large proportion of TLR2 ligands are lipopeptides that can bind
to theTLR2hydrophobic pocket, but someTLR2 ligands including
peptidoglycan, hyaluronic acid, teichoic acid, and zymosan do not
contain this hydrophobic region (Table 1). Hence, the interaction
of these ligands with TLR2 might use different binding sites. Fur-
ther crystallographic ormodeling studies are required to clarify the
exact binding sites of non-lipid ligands and to verify whether these
bindings induce the formation of similar heterodimeric structures
such as TLR1-2 or TLR2-6.
TLR3–dsRNA COMPLEX
Toll-like receptor-3 has been shown to recognize dsRNA pro-
duced during viral replication (Alexopoulou et al., 2001). The
ﬁrst TLR3 structure was identiﬁed independently by two differ-
ent groups (Bell et al., 2005; Choe et al., 2005). Both groups have
shown that the LRR region of TLR3 displays a heavily glycosy-
lated horseshoe-shaped solenoid structure. Choe et al. (2005),
postulated that dsRNA might bind at the convex surface because
this region is a glycan-free face, which enables dsRNA to bind
to the positively charged residues of the TLR ECD. However,
Bell et al. (2005) suggested that the nucleotide binding site is
located in the concave surface. This is likely due to the fact
that during crystallization, two sulfate molecules from the crys-
tallization medium stably bound to residues in LRRs 12 and
20, and these two LRRs contain large insertions. As the sulfate
ions share the same atomic arrangement as phosphate groups,
those present in the dsRNA backbone might be able to bind to
one or both of the sulfate binding sites. Hence, each group pre-
diction differs in the dsRNA binding sites and it was not clear
how TLR3 speciﬁcally recognizes dsRNA and initiates signaling.
However, the recently solved crystal structure of mTLR3 bound
to dsRNA explains how this is accomplished (Liu et al., 2008).
TLR3 ECD exists as a monomer in solution and the dimeriza-
tion only occurs upon ligand binding. In the structure, dsRNA
interacts with both the N- and C-terminal sites on the lateral
side of the convex surface of the TLR3 ECD (Figure 3A). The
N-terminal interaction sites are composed of LRRNT and LRR1-3
modules, whereas the C-terminal site is composed of LRR19-21
modules. The dsRNA in the complex retains a typical A-DNA
like structure, in which the ribose phosphate backbone and the
position of the grooves are the major determinants in binding
(Figure 3B). The mTLR3–ECD interacts with the sugar phos-
phate backbones, but not with individual bases, which accounts
for the lack of any particular nucleotide speciﬁcity in binding
(Alexopoulou et al., 2001; Leonard et al., 2008). This feature
would prevent the viruses from escaping detection by mutation
(Botos et al., 2011). Moreover, the identiﬁed structure reveals the
possible reasons for the inability of TLR3 to recognize dsDNA.
The helical structure of dsDNA is the B form, whereas dsRNA
is present in A form. The B form helical structure would not be
structurally compatible with the two terminal binding sites on the
TLR3–ECD. Moreover, several H-bonds were observed between
TLR3–ECD and the 2′-OH groups of dsRNA that is missing in
dsDNA.
The TLR3–TLR3 interaction site located near the LRRCT occu-
pies only a small portion, demonstrating that ligand–protein
interaction as the major driving force behind TLR3 dimeriza-
tion. The ligand interaction sites (two TLR3 ECD N-terminal
regions) are separated by about 120Å, thus showing why only
40–50 base pairs are sufﬁcient for the stabilized binding of dsRNA
to TLR3 (Leonard et al., 2008). However, there have also been
study reports of dsRNA of substantially less than 40 base pairs
being able to initiate TLR signaling (Kariko et al., 2004; Klein-
man et al., 2008). This raises the possibility that the N-terminal
interaction site is not essential for efﬁcient TLR3 signal induc-
tion in some experimental conditions.Moreover,mutation studies
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FIGURE 3 | Structure ofTLR3–dsRNA. (A) Ribbon structure of TLR3 dimer
(colored according to the secondary structure: helix-pink; sheet-yellow;
loop-green) bound with dsRNA (red). (B)Top view.
have identiﬁed functional amino acid residues in three differ-
ent regions (N-terminal, C-terminal, and dimerization region) of
the TLR3 ECD. H539E and N541A mutation in the C-terminal,
H39A/E and H60A/E mutation in the N-terminal region, and
D648A, T679A, and P680L in the dimerization region leads to
a loss of TLR3 activity (Bell et al., 2006; Ranjith-Kumar et al.,
2007; Fukuda et al., 2008; Wang et al., 2010). Although hydropho-
bic interactions play a crucial role in binding of lipopeptides
to TLR1/2 and 2/6, the TLR3 interaction with dsRNA mainly
involves electrostatic interactions and H-bonds. Despite these
differences in ligand interactions, the ligand-induced dimers of
TLR3, TLR2-6, and TLR1-2 adopt a similar fold, the “m” shaped
dimer, in which the two C-termini of the TLR ECDs are in prox-
imity, thereby bringing the two TIR domains together on the
cytoplasmic side and providing a scaffold for the recruitment of
adaptor proteins and subsequent initiation of further downstream
signaling.
TLR4–MD-2-AGONIST/ANTAGONIST COMPLEX
A crystal structure of human TLR4–MD-2 complex binding with
an antagonist (Eritoran) has been described (Kim et al., 2007b).
Unlike other TLRs that recognize ligands directly, TLR4 does not
directly interact with ligands. Alternatively, TLR4 forms a stable
1:1 heterodimer with MD-2 and uses the hydrophobic pocket in
MD-2 to interact with the LPS of Gram-positive bacteria (Shimazu
et al., 1999). Two accessory proteins such as lipid-binding protein
(LBP) and CD14, whose main function is to extract LPS from
the bacterial membrane and transferring it efﬁciently into MD-2.
The general structure of bacterial LPS consists of a hydrophobic
lipid A domain, an oligosaccharide core and a distal polysaccha-
ride (the O antigen; Bryant et al., 2010). Lipid A moiety alone is
sufﬁcient to activate innate immune responses. Lipid A consists of
a diglucosamine diphosphate head group that is substituted with
a variable number of acyl chains, ranging from four to eight. In
general, lipidAmoieties consisting of hexa acylated lipid chain and
two phosphate groups are powerful immune stimulators, whereas
Lipid A with ﬁve acyl chains have ∼100-fold less activity. Several
synthetic derivatives of lipid A have been developed as candidate
drugs against sepsis and septic shock syndrome. Eritoran or E5564
is a synthetic molecule derived from the lipid A component of
non-pathogenic LPS of Rhodobacter sphaeroides. This compound
contains only four acyl chains and acts as a strong antagonist of
TLR4–MD-2 complex and is currently in Phase III clinical trial
(Mullarkey et al., 2003; Rossignol and Lynn, 2005).
Toll-like receptor-4 ECD has 22 LRRs capped by LRRNT and
LRRCT at its N- and C-termini, respectively. MD-2 has a cup fold
like structure and is composed of antiparallel β sheets forming a
large hydrophobic core, with the surface area of ∼1000Å that is
able to bind with ligand. The opening of the pocket is lined with
positively charged residues and three disulﬁde bridges that stabi-
lize the cup-like structure. It should be noted that MD-2 does not
have either a transmembrane or an intracellular domain; hence it
is not able to transmit the signals. Recent TLR4 andMD-2 complex
clearly indicated that only one-third of MD-2 is involved in TLR4
binding, the remaining part is available for the interaction with
ligands (Kim et al., 2007b; Park et al., 2009). The MD-2 binding
site of TLR4 can be divided into two chemically and evolutionary
distinct areas, termed as A and B patches. The A patch is provided
by the N-terminal domain of TLR4, which is mainly comprised of
negatively charged amino acids. The B patch is located in the cen-
tral domain that is predominantly comprised of positively charged
residues. The TLR4 binding surface of MD-2 shows a clear charge
complementarity to the TLR4 surface (Figure 4E). In the crystal
structure, four acyl chains of Eritoran occupy approximately 90%
of the solvent accessible volume of the MD-2 pocket. Of those,
two acyl chains are in the fully extended conformation within the
binding pocket,while the remaining two acyl chains are bent in the
middle (Figure 4A). The diglucosamine backbone is fully exposed
to the solvent and the phosphate groups make ionic contacts with
positively charged residues at the surface of the pocket. Addition-
ally, there is no direct interaction betweenEritoran andTLR4 (Kim
et al., 2007b). Indeed, this is very similar to the recently identiﬁed
structure of MD-2 in complex with the lipid IVA (Figure 4B; Ohto
et al., 2007). Lipid IVA, or compound 406, is an intermediate in
LPS biosynthesis, which contains four lipid chains with lengths
and structures that differ from the Eritoran. Lipid IVA acts as
an antagonist of human TLR4–MD-2, but behaves as an agonist
of mouse TLR4–MD-2 (Means et al., 2000). Despite the signiﬁ-
cant structural differences seen between lipid IVA and Eritoran,
their binding modes are similar. The structural superimposition
of TLR4–MD-2–Eritoran and MD-2–lipid IVA have shown that
lipid chains of different lengths are accommodated in the MD-2
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FIGURE 4 |The interactions of agonist and antagonistic ligands in
TLR4–MD-2 complex. (A)WhenTLR4–MD-2 binds to Eritoran, the F126 loop
is exposed to the solvent area. (B)When MD-2 binds to lipid IVA, the F126
loop is exposed to the solvent area. (C)WhenTLR4–MD-2 binds to LPS; the
F126 loop forms hydrophobic interactions with lipid chains and the second
TLR4. This interaction causes a structural shift in the F126 loop, which enables
the correct positioning of the R2 lipid chain to interact with the secondTLR4
as well as TLR4 dimerization to occur. (D) Structure of TLR4–MD-2–LPS
complex. TLR4, MD-2, and LPS are colored in magenta, light green,
and red, respectively. (E)TLR4–MD-2 dimer interface formed by
electrostatic interaction. Positive and negative charged residues are
marked in blue and red color, respectively. (F)TLR4 homodimer interface.
Hydrophilic and hydrophobic residues are colored in green and khaki,
respectively.
pocket with only a 2-Å shift in the glucosamine backbone (Kim
et al., 2007b). In both lipid IVA–MD-2 and Eritoran-TLR4–MD-2
structures, the ligands did not induce any conformational changes
in the receptors, thereby demonstrating that these molecules are
antagonists.
The much anticipated TLR4–MD-2–LPS complex has recently
been solved (Park et al., 2009). The authors demonstrated that
TLR4 and MD-2 proteins associate with each other without LPS,
but the dimerization of the TLR4–MD-2 complex with another
TLR4–MD-2 occurs only via binding of LPS. The receptor multi-
mer is composed of two copies of the TLR4–MD-2–LPS complex
arranged in a symmetrical fashion (Figure 4D). In the crystal
structure, ﬁve of the six lipid chains of LPS bind to this pocket,
while the remaining lipid chain that is exposed on the surface
of MD-2 forms hydrophobic interactions (F440, F463, and L444)
with the second TLR4 (Figure 4C). Mutation of the F440 and
F463 interface residues disrupt TLR4 dimerization and its signal-
ing (Resman et al., 2009). The binding of LPS induces localized
conformational changes in MD-2, primarily on the F126 loop
region, which leads to the hydrophilic residues in the F126 loop
and R90 residues of MD-2 form H-bonds and ionic interac-
tions with the second TLR4, further stabilizing the complex. In
addition to the above major interaction, TLR4 makes an addi-
tional contribution to dimerization by directly interacting with
second TLR4 (Figure 4F). The previously solved MD-2 bound to
the Eritoran and lipid IVA structures revealed that F126 of MD-2
was exposed to the solvent, thereby showing no conformational
changes and hence MD-2 complex was unable to induce TLR4
dimerization. Park et al. (2009) clearly demonstrated that struc-
tural changes that mainly occurred at the F126 loop of MD-2
following LPS simulation are necessary for the dimer forma-
tion and subsequent initiation of downstream signaling.Mutation
studies of the F126 residue of MD-2 supports this ﬁnding. The
mutation of F126 did not affect LPS binding; however, it abol-
ished the ability of the TLR4–MD-2 heterodimer to form the
activated heterotetramer, suggesting that these residues form part
of the dimerization region (Kobayashi et al., 2006; Kim et al.,
2007b). Moreover, LPS contain two phosphate groups that are
important for forming ionic interactions with positively charged
residues on both TLR4 and MD-2. Comparison of LPS bound
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MD-2 with Eritoran–MD-2 indicates that the additional two lipid
chains in LPS displace the phosphorylated glucosamine back-
bone upward by 5Å toward the solvent area, which allows the
phosphate groups to associate with the second TLR4 (Park et al.,
2009). In addition to the displacement, the glucosamine backbones
are also rotated by 180˚, interchanging the phosphate groups. It
should be noted that there is a general rule for TLR signaling
(based on the structural and biochemical studies); speciﬁcally,
TLR agonists induce TLR dimerization, whereas antagonists are
likely to interfere with dimerization (Brodsky and Medzhitov,
2007).
Crystallographic studies have provided almost 50% of the
mammalian TLR structures (TLR1, 2, 3, 4, and 6), which have
provided a basis for the understanding of agonistic induced TLR
activation and antagonistic mediated TLR inhibition. Each TLR
member recognizes “n” number of ligands starting from the
microbes, and each ligand has its own unique properties. From
this review, we come to know that the binding sites of these lig-
ands cannot be similar in all TLRs. For example, TLR4 recognizes
various ligands (Table 1), but the binding site of those ligands
are not the same as LPS in TLR4–MD-2 complex. X-ray crys-
tallographic studies have revealed that there are only a limited
number of TLR ECD interactions with ligands. The identiﬁcation
of all ligand interactions with each TLRmember (listed in Table 1)
using X-ray crystallographic studies have proven to be very difﬁ-
cult. Hence, we have to rely on molecular modeling studies along
with biochemical validation, to gain further insights into these
interactions.
COMPUTATIONAL STUDIES OF THE TLR ECD
To date, approximately 20 molecular modeling studies have inves-
tigated on TLR signaling. These studies include: (i) prediction
of TLR ECD using available TLR crystal structures as a template
and identiﬁcation of its possible ligand-binding region. (ii) Struc-
tural basis identiﬁcation of positive and negative regulators in
TLR signaling and (iii) Identiﬁcation of the interaction between
the TIR domain and its adaptor molecules, which provides struc-
tural insights into the mechanism responsible for TLR mediated
downstream activation or inhibition.
The ﬁrst modeling study reported the structures of the mouse
(m) and human (h) TLR4 ECD. These structures were generated
using the ﬁrst solved hTLR3 structure as a template (Kubarenko
et al., 2007). Their target–template alignment showed that N-
terminal and C-terminal domains aligned with the template, but
the central domain did not align well. Hence, the alignment of
this portion was conducted individually by matching LRRs in
hTLR3. These sub domains (N-terminal, C-terminal, and indi-
vidual LRRs) were manually assembled and subjected to MD
simulation. Their analysis revealed that the central domain of
TLR4 ECD (LRR9-13) is hypervariable across human and mouse.
It should be noted that the ECDs of TLR7 and 9 are cleaved in the
endolysosome to recognize ligands, and this cleaved form is nec-
essary for Myd88 activation (Kawai and Akira, 2010; Basith et al.,
2011b). Wei et al. (2009) generated structural models of cleaving
ligand-binding domains of TLR7, 8, and 9. Based on comparison
of the structures, they have identiﬁed potential ligand-binding
sites as well as possible conﬁgurations of the receptor–ligand
complexes. Conversely, Kubarenko et al. (2010) modeled full
length ECD structures of TLR7, 8, and 9. Structural compar-
ison of these ECDs revealed that the insertion mainly takes
place in the TLR9 loop regions (LRR2, 5, and 8), which con-
tains primarily cysteine and few proline residues (Kubarenko
et al., 2010). Finally, the loop insertion residues have been
quantiﬁed through biochemical studies and identiﬁed the func-
tional role of these residues (C98, C110, P183, C184, C265,
C268, and P269) in TLR9 signaling. The ﬁrst modeling report
to show the ligand binding to the TLR ECD is TLR5, whose
concave surface interacts with ﬂagellin and the biochemical
studies provided that D296 and D367 of TLR5 are neces-
sary for mediating this interaction (Andersen-Nissen et al.,
2007).
Recently, the LRRML and TollML tools were designed to iden-
tify appropriate templates for each LRR and the functional anno-
tation of TLR primary sequences, respectively (Wei et al., 2008;
Gong et al., 2011). LRRML, the program produces the alignment
for each LRR along with templates that were subsequently used for
homology modeling of LRR proteins. Generally, one or more full
length protein has been used as a template for modeling. However,
due to variations in the LRRnumbers amongTLRs, sequenceswith
low similarity between the target and full length template are usu-
ally not sufﬁcient for homology modeling. The LRRML tool was
developed to address this issue. This tool currently contains 1261
individual LRRs (obtained from 112 PDB structures) that serve
as a local template for each target. As a test case, the developers
modeled the structure of the mouse TLR3 ECD and excluded the
LRRs of the mouse/human TLR3 ECD from the LRRML dataset.
The ﬁnal 26-line multiple alignments were generated by 25 tem-
plate sequences and the target sequences were used for modeling.
Superimposition of the modeled TLR3 structure with the actual
TLR3 crystal structure revealed an RMSD value of 1.9 Å, con-
ﬁrming the reliability of modeling studies. This method has since
been used to predict series of human TLR5-10 and mouse 11–13
(Wei et al., 2010). These models can be used to conduct ligand
docking studies or design mutagenesis experiments to investi-
gate the TLR–ligand-binding mechanism. Recent studies by our
group have shown that the Pam3CSK4 might be the ligand for the
TLR2/10 complex and Pam2CSK4 might activate TLR10/6 and
TLR10 homodimer. The predicted TLR10 complexes are similar
to the available TLR1 family complexes. However, the binding ori-
entation of TLR10 homodimer was different due to the presence
of negatively charged surface near LRR11-14, that deﬁned the spe-
ciﬁc binding pocket (Govindaraj et al., 2010). This has been the
ﬁrst study to suggest the possible ligands for TLR10. Our predic-
tions were also conﬁrmed by the recent biochemical studies by
showing that chimeric receptors [TLR10 ECD and endodomain
(TIR) TLR1] along with TLR2 recognize triacylated lipopeptides
(Guan et al., 2010).
It iswell known that lipid IVAacts as an agonist or antagonist for
TLR4–MD-2 complex,depending upon the species. To identify the
species speciﬁcity,Walsh et al. (2008) conducted modeling studies
and identiﬁed differences in primary sequences among the species
(mouse, cat, horse, and human). Mouse, cat and horse species
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were able to induce signaling in response to lipid IVA, whereas
human species were not able to induce signaling, primarily due to
the conservative substitution. However, this reason alone cannot
be expected to have a large inﬂuence on the overall structure of
the protein. Furthermore, they identiﬁed signiﬁcant differences in
the local charge distribution on the surfaces of MD-2 and TLR4
from different species, which suggests that electrostatic forces also
govern the pharmacology of lipid IVA, further leading to the trans-
duction of TLR4 signaling. In general, the assembly of active TLR4
complexes is a stepwise process, with initial TLR4–MD-2 complex
formation being induced by the binding of lipid IVA, further pro-
moting the subsequent homodimerization of receptor ECDs. In
themodeled complex structure,LRR15–17moduleswere found to
participate in the main dimerization interface of TLR4. Their pre-
dicted modeling and mutagenesis data were remarkably accurate
when the LPS bound TLR4–MD-2 crystal structure was released
(Park et al., 2009).
African swine fever viruses (ASFV) encode a novel protein
(pI329L) that has been shown to inhibit TLR3 signaling pathway.
Modeling studies have shown that pI329L structural arrangement
is similar to TLRs (Henriques et al., 2011). However, the dif-
ference observed in ECD of pI329L, which is shorter than the
TLR. This protein forms a heterodimer with TLR3, thus acting
like a decoy receptor, demonstrating that viral protein hinders
the TLR3 homodimerization, and thereby inhibiting the TRIF
mediated pathways. A recent study showed that the pentameric
B subunit of type IIb Escherichia coli enterotoxin (LT-IIb-B5),
a non-lipidated protein ligand, activates TLR2/1 signaling path-
ways. Molecular modeling along with mutagenesis studies showed
that the upper pore of LT-IIb-B5 (M69E, A70D, L73E, and S74D)
deﬁnes an interactive surface for binding with the concave sur-
face of the TLR2/1 central domain (Liang et al., 2009). Unlike
TLR2–TLR1–triacylated lipopeptide complex, non-lipidated lig-
ands cannot ﬁt into the small hydrophobic channel; however,
these ligands can engage in TLR surface interactions via speciﬁc
residues.
TIR MEDIATED DOWNSTREAM ACTIVATION AND
INHIBITION
Toll-like receptor ECD activation leads to TIR dimerization of
TLRs, which creates speciﬁc scaffold for the binding of adaptor
proteins such as Myd88, Mal, TRIF, and TRAM. This assembly
of the TIR complexes activates the downstream signaling path-
ways, leading to the expression of pro-inﬂammatory cytokines,
antiviral response and also in the initiation of adaptive immu-
nity. To date, ﬁve mammalian TIR structures have been reported
(TLR1, TLR2, TLR10, IL-1RAPL, and Myd88; Xu et al., 2000;
Tao et al., 2002; Khan et al., 2004; Nyman et al., 2008; Ohnishi
et al., 2009). All these TIR domains, containing alternative β
strands and α helices are arranged as a central ﬁve stranded
parallel β sheets surrounded by α helices. The TIR domains of
TLR1 and TLR2 exist as a monomer in the crystal. Conversely,
TLR10 TIR domain without the extracellular and transmem-
brane regions behaves as a monomer in solution, but it forms
a homodimer in the crystal asymmetric unit. This structure
has been used to represent the signaling dimer of TIRs. In the
TLR10 TIR dimer interface, BB-loop connecting the βB strand
and the αB helix, and the death domain (DD) loop connect-
ing the βD strand and the αD helix, have been reported to be
important for the downstream signaling. Moreover, part of the
BB-loop exposed to the surface is essential for the binding of
the adaptor proteins during signal transduction (Nyman et al.,
2008).
On the basis of TLR10 TIR structure, TLR4 TIR homod-
imer has been modeled by computational studies and identiﬁed
two symmetrically related interfaces that are potentially capa-
ble of binding to adaptors, Mal and TRAM (Figure 5; Nunez
Miguel et al., 2007). It is of worth noting that TLR4 TIR P681H
polymorphism variation has been reported to abolish signal in
response to LPS. In fact, this P681 located at the BB-loop, high-
lights its importance in TIR dimerization. Moreover, this model
indicates that two adaptors could bind simultaneously to the
TLR4 TIR dimer. Another important question raised by this
study is whether adaptors binding is mutually exclusive, that is
whether a single activated receptor complex recruits either Mal
or TRAM, but not both simultaneously. Kagan et al. (2008)
suggested that TLR4 signaling via Mal–Myd88 occurs at the
plasma membrane and the signaling via TRAM–TRIF might be
endosomal.
The crystal structures of bacterial (Chan et al., 2010) and
the plant TIR domains (Chan et al., 2009) are highly homol-
ogous to those of mammalian TIRs. In bacterial TIR domain,
the dimerization interface involves DD loop but not the BB-loop
(important for TLR10 dimer). Chan et al. (2009) suggest that
FIGURE 5 | Molecular model of MAL andTRAMTIR domains bridged to
the activatedTLR4TIR domains.The BB-loops in eachTIR domain are
highlighted in red. MAL andTRAM proteins are both predicted to bind to
theTLR4 homodimer interface. It is probable that binding of MAL or TRAM
protein is mutually exclusive, with the former binding to activated receptors
at the cell surface and the latter in endosomes.
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the BB-loop is not important for the homotypic interactions but
may have a deﬁned role in the heterotypic interactions with Mal
or Myd88 TIR domains. Moreover, the available TIR structures
lack the region immediately following their transmembrane seg-
ment, further making it hard to predict their exact orientation.
Myd88 contains an N-terminal DD that is separated from the
C-terminal TIR domain by a short linker sequence. After bind-
ing of Myd88 TIR domain to TLR TIR domains, Myd88 DD
can interact with DD members of IRAK family, to activate their
downstream signaling cascades. Recently, Lin et al. (2010) iden-
tiﬁed the complex crystal structures formed by DD of Myd88,
IRAK4, and IRAK2. This complex structure known as Myd-
dosome, consists of left handed helical structure in the order
of 6 Myd88, 4 IRAK4, and 4 IRAK2 DDs. Like TIRs, DD are
small globular proteins but have an anti parallel α helical fold
rather than α–β structure. The dimerization of TLR TIR dimer
recruits two Myd88 TIR domains then the larger myddosome
superhelix could possibly bridge several activated receptor dimer
in the network (Gay et al., 2011). Polymorphism of S34Y and
R98C in the human DD, interfere with the myddosome assem-
bly and may contribute susceptibility to infection (George et al.,
2011).
Single immunoglobulin interleukin-1 receptor TIR domain
(SIGIRR) and ST2L, belong to the TIR/IL-1R superfamily, which
act as a negative regulator of Myd88-dependent TLR signaling.
Speciﬁcally, this family attenuates the recruitment of Myd88 adap-
tors to the receptors via its intracellular TIR domain. Thus, these
molecules are highly important for the treatment of autoimmune
diseases caused by TLRs. Gong et al. (2010) proposed a residue
detailed structural framework of SIGIRR inhibiting the TLR4
and 7 signaling pathways. In their multimer complex, SIGIRR
exerts its inhibitory effect by blocking the molecular interface of
TLR4, TLR7, and Myd88 adaptors, mainly via its BB-loop region.
Our group proposed a structural framework of ST2L inhibiting
the TLR4, TLR2/1, and TLR2/6 signaling pathways (Basith et al.,
2011a). Apart from this, our group identiﬁed the structure based
modulation of IκB family proteins. These proteins are structurally
similar that are activated by TLR signaling and it has speciﬁc
role in the cytoplasm and the nucleus by interacting with dif-
ferent subunits NF-κB dimer. Although the structures are similar,
the binding speciﬁcities of these proteins remain unknown. The
modeling studies have identiﬁed that variation in charged surfaces
among the IκB proteins and also differences in the ﬂexible resid-
ual position might be the chief factor for the IκB protein binding
speciﬁcities (Manavalan et al., 2010, 2011).
CONCLUSION
In the past few years, there has been tremendous progress in the
study of interaction of TLRs with their ligands and activators.
Herein, we have discussed recent structural information regarding
the TLR family and its proposed activation and inhibition mecha-
nisms. Recent crystallographic studies of TLR1/2,2/6,4, and 3have
provided an explanation for in vivo, in vitro, and clinical observa-
tions. The solved structures have demonstrated that TLR exists as a
monomer in solution and that dimerization takes place only upon
ligand binding. Conversely, TLR8 and 9 exist as preformed dimers
that subsequently change the conformation upon ligand binding.
The solved (TLR1, 2, 6, 3, and 4) and modeled TLR ECD struc-
tures appear to have a common fold that belong to a well known
LRR family with repeated LRR modules. Sequence and structural
analyses indicate that TLRs present in the extracellular membrane
(TLR1, 2, 4, 6, and 10) belong to a three-domain subfamily that
binds to hydrophobic ligands such as lipoprotein, LTA and LPS.
Conversely, TLRs present in the endolysosome (TLR3, 7, 8 and 9)
belong to a single domain family that interacts with hydrophilic
proteins or nucleic acids. This ligand-induced dimerization leads
to the juxtamembrane sequences at the C-terminal ECDs com-
ing into close proximity. These sequences are then transmitted
across the transmembrane, resulting in reorientation or homod-
imerization between the receptor TIR domains. The homodimeric
receptor TIR domains provide speciﬁc molecular surfaces for the
recruitment of adaptor TIR domains. Although the structures of
the TLRs are similar, the binding pocket and electrostatic sur-
faces are not conserved among these receptors. These variations
are mandatory for the discrimination of the ligand speciﬁcity
in each TLR family member. For example, triacylated lipopep-
tides bind to the hydrophobic binding pocket of TLR1/2; however,
LT-IIb-B5 protein binds to the same receptor on another surface
rather than the hydrophobic pocket. This is primarily due to the
patterns present in the ligands with different properties (lipids
and proteins), which causes the binding site of ligands to vary
among all TLRs according to the surface and cavity provided by
the receptors.
It is essential that we continue to develop a thorough and
detailed understanding of the structural or molecular interac-
tions of the ligands listed in Table 1 with their corresponding
TLR family members. Such studies facilitate the rational design of
receptor agonists and antagonists, leading to potential improve-
ments in the treatment of diseases. However, there are still many
important unanswered questions about TLR signaling. For exam-
ple, the conformation of the transmembrane spanning segment
once the TLR ECDs are activated is not known. The process
leading to the recruitment of adaptor proteins following TLR acti-
vation is also not clear. Furthermore, it is not known if other
ligands bind to the receptors in the same orientation and induce
similar “m” shaped dimerization as seen in crystal structures.
TLR4 receptor activation requires a co-receptor such as MD-2,
but further work is needed to determine if this mechanism holds
true for TLR4 designed agonists and if these synthetic agonists
also need a co-receptor to bind with TLR receptor. The recent
advances that have been made in structure–function analyses
should allow many of these questions to be resolved in the near
future.
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